MCID: PLC007
MIFTS: 47

Placental Abruption

Categories: Fetal diseases, Reproductive diseases

Aliases & Classifications for Placental Abruption

MalaCards integrated aliases for Placental Abruption:

Name: Placental Abruption 12 73 15
Abruptio Placentae 12 54 17 70
Abortion, Threatened 44
Abruptio Placenta 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9667
ICD9CM 34 640.0
MeSH 44 D000033
NCIt 50 C112857
SNOMED-CT 67 54048003
ICD10 32 O20.0
UMLS 70 C0000821 C0000832

Summaries for Placental Abruption

Disease Ontology : 12 A placenta disease that is characterized by separation of the placental lining from the uterus of the mother.

MalaCards based summary : Placental Abruption, also known as abruptio placentae, is related to prothrombin thrombophilia and factor xii deficiency. An important gene associated with Placental Abruption is MTHFR (Methylenetetrahydrofolate Reductase), and among its related pathways/superpathways are Formation of Fibrin Clot (Clotting Cascade) and Complement and coagulation cascades. The drugs Sevoflurane and Dydrogesterone have been mentioned in the context of this disorder. Affiliated tissues include placenta, uterus and endothelial, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 73 Placental abruption is when the placenta separates early from the uterus, in other words separates... more...

Related Diseases for Placental Abruption

Diseases related to Placental Abruption via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 314)
# Related Disease Score Top Affiliating Genes
1 prothrombin thrombophilia 32.4 MTHFR F2
2 factor xii deficiency 31.9 SERPINC1 F5 APOH
3 placenta praevia 30.9 PGF PAPPA F2
4 disseminated intravascular coagulation 30.9 THBD SERPINC1 F5 F2
5 severe pre-eclampsia 30.9 SERPINC1 PGF PAPPA HLA-G F5 APOH
6 hellp syndrome 30.8 THBD SERPINC1 PGF MTHFR FLT1 F5
7 myelomeningocele 30.5 MTRR MTHFR MTHFD1
8 neural tube defects, folate-sensitive 30.4 MTRR MTHFR MTHFD1
9 preeclampsia/eclampsia 1 30.4 SERPINC1 NOS3
10 oligohydramnios 30.3 PGF PAPPA AGT
11 anencephaly 30.3 MTRR MTHFR MTHFD1
12 thrombophilia 30.3 THBD SERPINC1 MTHFR F5 F2 APOH
13 pregnancy loss, recurrent 1 30.3 HLA-G F5 APOH
14 pulmonary edema 30.2 SERPINC1 NOS3 F2
15 cerebral palsy 30.2 SERPINC1 PTGS2 NOS3 MTHFR F5 F2
16 cerebrovascular disease 30.2 THBD MTHFR F5 F2 APOH AGT
17 ectopic pregnancy 30.1 PGF PAPPA FLT1
18 dysfibrinogenemia, congenital 30.1 THBD SERPINC1 F5 F2
19 thrombophilia due to activated protein c resistance 30.0 THBD SERPINC1 MTHFR F5 F2 APOH
20 intracranial thrombosis 30.0 SERPINC1 MTHFR F5 F2 APOH
21 thrombotic thrombocytopenic purpura 29.9 THBD SERPINC1 APOH
22 migraine with or without aura 1 29.9 PTGS2 NOS3 MTHFR F2 APOH
23 purpura 29.9 THBD SERPINC1 F2 APOH
24 thrombophilia due to thrombin defect 29.8 THBD SERPINC1 MTHFR F5 F2 APOH
25 respiratory failure 29.8 THBD SERPINA7 PTGS1 F2
26 placenta accreta 29.8 PGF PAPPA FLT1
27 thrombocytopenia 29.8 THBD SERPINC1 MTHFR F5 F2 ENG
28 antiphospholipid syndrome 29.8 THBD SERPINC1 MTHFR F5 F2 APOH
29 blood coagulation disease 29.7 THBD SERPINC1 MTHFR F5 F2 APOH
30 thrombosis 29.6 THBD SERPINC1 MTHFR F5 F2 APOH
31 neonatal anemia 29.6 PGF PAPPA FLT1 ENG
32 twin-to-twin transfusion syndrome 29.6 PGF PAPPA FLT1 ENG
33 homocysteinemia 29.5 THBD SERPINC1 NOS3 MTRR MTHFR F5
34 down syndrome 29.4 PGF PAPPA MTRR MTHFR
35 placenta disease 29.2 SERPINC1 PGF PAPPA MTHFR HLA-G FLT1
36 placental insufficiency 29.2 SERPINC1 PGF PAPPA FLT1 F2
37 stroke, ischemic 29.1 THBD SERPINC1 NOS3 MTHFR F5 F2
38 pre-eclampsia 29.0 THBD SERPINC1 PGF PAPPA NOS3 MTHFR
39 eclampsia 29.0 THBD SERPINC1 PGF PAPPA NOS3 MTHFR
40 vascular disease 28.4 THBD SERPINC1 PTGS2 PTGS1 NOS3 MTRR
41 hypertension, essential 27.7 THBD SERPINC1 PTGS2 PTGS1 PGF PAPPA
42 factor v leiden thrombophilia 11.2
43 preterm premature rupture of the membranes 10.6
44 chorioamnionitis 10.5
45 paracetamol poisoning 10.4 F5 F2
46 amaurosis fugax 10.4 MTHFR F5
47 hemifacial spasm 10.4 NOS3 MTHFR
48 may-thurner syndrome 10.4 F5 APOH
49 total spina bifida aperta 10.4 MTHFR MTHFD1
50 cervicothoracic spina bifida aperta 10.4 MTHFR MTHFD1

Graphical network of the top 20 diseases related to Placental Abruption:



Diseases related to Placental Abruption

Symptoms & Phenotypes for Placental Abruption

GenomeRNAi Phenotypes related to Placental Abruption according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-2 9.36 FLT1
2 Decreased viability GR00249-S 9.36 AGT F5 HLA-G NOS3
3 Decreased viability GR00386-A-1 9.36 AGT HLA-G MTHFD1 MTHFR NOS3 SERPINA7

MGI Mouse Phenotypes related to Placental Abruption:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.32 AGT APOH BHMT ENG F2 F5
2 growth/size/body region MP:0005378 10.31 AGT BHMT ENG F2 F5 FLT1
3 cardiovascular system MP:0005385 10.3 AGT ENG F2 F5 FLT1 MTHFD1
4 immune system MP:0005387 10.13 AGT BHMT EBAG9 F2 FLT1 HLA-G
5 embryo MP:0005380 10.09 ENG F2 F5 FLT1 MTHFD1 PGF
6 mortality/aging MP:0010768 9.97 AGT APOH ENG F2 F5 FLT1
7 liver/biliary system MP:0005370 9.86 AGT BHMT F5 MTHFR NOS3 PTGS2
8 muscle MP:0005369 9.56 AGT ENG F2 FLT1 NOS3 PTGS1
9 nervous system MP:0003631 9.44 AGT BHMT ENG F2 F5 FLT1

Drugs & Therapeutics for Placental Abruption

Drugs for Placental Abruption (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 41)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
2
Dydrogesterone Approved, Investigational, Withdrawn Phase 4 152-62-5 9051
3 Anesthetics Phase 4
4 Analgesics Phase 4
5 Tocolytic Agents Phase 4
6 Platelet Aggregation Inhibitors Phase 4
7 Anesthetics, General Phase 4
8 Anesthetics, Inhalation Phase 4
9
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
10
Salicylic acid Approved, Investigational, Vet_approved Phase 3 69-72-7 338
11
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
12
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
13 Anti-Arrhythmia Agents Phase 3
14 Anticonvulsants Phase 3
15 calcium channel blockers Phase 3
16 Calcium, Dietary Phase 3
17 Fibrinolytic Agents Phase 3
18 Analgesics, Non-Narcotic Phase 3
19 Cyclooxygenase Inhibitors Phase 3
20 Antirheumatic Agents Phase 3
21 Antipyretics Phase 3
22 Anti-Inflammatory Agents Phase 3
23 Anti-Inflammatory Agents, Non-Steroidal Phase 3
24 Hormones Phase 3
25 Hormone Antagonists Phase 3
26 Progestins Phase 3
27 Pharmaceutical Solutions Phase 3
28
Calcium Nutraceutical Phase 3 7440-70-2 271
29
Indomethacin Approved, Investigational 53-86-1 3715
30
Enoxaparin Approved 9005-49-6 772
31
Misoprostol Approved 59122-46-2 5282381
32 Factor VIII
33 Immunoglobulins, Intravenous
34 Antibodies
35 Immunoglobulins
36 gamma-Globulins
37 Rho(D) Immune Globulin
38 Anticoagulants
39 Complement System Proteins
40 Hemostatics
41 Coagulants

Interventional clinical trials:

(show all 30)
# Name Status NCT ID Phase Drugs
1 Progesterone Supplementation in Threatened Abortion: Is it a Sound Practice? Completed NCT03930212 Phase 4 Progesterone;Placebos
2 Effect of Sevoflurane on the Success of External Cephalic Version for Breech Presentation Not yet recruiting NCT04346823 Phase 4 Sevoflurane
3 Oral Progesterone for Prevention of Miscarriage in Threatened Abortion: a Randomized, Double-blinded, Placebo-controlled Trial Not yet recruiting NCT04788108 Phase 4 Dydrogesterone;Placebo
4 Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM) Completed NCT00014989 Phase 3 magnesium sulfate
5 A Randomized Double-blind Controlled Trial of Use of Dydrogesterone in Women With Threatened Miscarriage in the First Trimester Completed NCT02128685 Phase 3 Dydrogesterone;Placebo
6 Chronic Hypertension and Acetyl Salicylic Acid in Pregnancy, a Multicenter Prospective Randomized Double-blind Placebo-controlled Trial. Recruiting NCT04356326 Phase 3 Aspirin 150 mg;Placebo
7 Prospective, Double-blind, Randomised, Placebo Controlled, Phase III Clinical Study Assessing the Efficacy of Natural Progesterone 25 mg/Bid Administered Subcutaneously in the Maintenance of Early Pregnancy in Women With Symptoms of Threatened Abortion Terminated NCT02950935 Phase 3 Progesterone;Placebo
8 Impact of the NO-donor Pentaerythrithyltetrantrate on Perinatal Outcome in High-risk Pregnancies: a Prospective Randomized Pilot Study Completed NCT01355822 Phase 1, Phase 2 PETN;Placebo control
9 Chinese Herbal Medicine and Micronized Progesterone for Live Births in Threatened Miscarriage: An International Cooperative Multicenter Randomized Controlled Trial Recruiting NCT02633878 Phase 2 Chinese Herbal Medicine plus Progesterone Capsules;Chinese Herbal Medicine Placebo plus Progesterone Capsules Placebo;Chinese Herbal Medicine plus Progesterone Capsules Placebo;Chinese Herbal Medicine Placebo plus Micronized Progesterone
10 A Retrospective Analysis of Possible Association Between Severe Pregnancy Complications and Elevated Factor VIII Plasma Activity. Unknown status NCT00573118
11 Biochemical Versus Ultrasound Findings as Predictors of Fetal Loss in Cases of First Trimester Threatened Miscarriage Unknown status NCT03797508
12 Vaginal Progesterone for Treatment of Threatened Miscarriage; Randomized Clinical Trial Unknown status NCT02690129 Vaginal Progesteron
13 Retrospective Descriptive Study on Retroplacental Hematomas in Finistère Completed NCT04168606
14 Randomized, Double Blind Trial of Magnesium Sulfate Tocolysis Versus Intravenous Saline for Suspected Placental Abruption Completed NCT00186069 Magnesium Sulfate
15 Comparison of Maternal Neonatal Outcomes of Normotensive and Hypertensive Placental Abruptions: A Novel Approach Completed NCT04449601
16 Dose Adjusting Enoxaparin Thromboprophylaxis Dosage According to Anti-factor Xa Plasma Levels Improve Pregnancy Outcome Completed NCT01068795 enoxaparin
17 Dynamics of Serum Immunologic Markers Levels in During the Delivery and Possible Benefit for Obstetric Emergency Diagnostics Completed NCT03664999
18 Assessment of Non-medical Use of Misoprostol in Case of Miscarriage or Threatened Miscarriage in Guadeloupe. Completed NCT03358940
19 Thromboelastometry Prediction Utility for Risk of Abortion Completed NCT03548701
20 Multicenter Open Prospective Comparative Non-interventional Study of Therapy for Threatened Miscarriage With Medicinal Products Utrogestan, 200 mg Capsules (Besins Healthcare SA, Belgium), and Duphaston, 10 mg Coated Tablets (Abbott Healthcare Products B.V., the Netherlands) Completed NCT03309735 Micronized progesterone;Micronized progesterone;Dydrogesterone
21 Color Doppler of CL and Uterine Artery With Serum Progesterone and CA125 in Threatened Abortion Completed NCT02420769
22 Value of CA125 and Yolk Sac Morphology in Prediction of Pregnancy Outcome in Threatened Miscarriage Completed NCT03320213
23 Pregnancy Dating Test - The Fall of hPL in Urine Over Time Completed NCT04217200
24 Pregnancy Outcome in Woman With Threatened Abortion Completed NCT02686112
25 REGISTRO EPIDEMIOLOGICO DE COVID 19 EN GESTANTES Recruiting NCT04558996
26 Evaluation of the Serum Markers sFLt1 and PlGF for the Prediction of the Complications of the Placental Vascular Pathologies in the 3rd Quarter of the Pregnancy. Recruiting NCT03455387
27 Plasma Concentration of Biological Markers in Placental Abruption Active, not recruiting NCT03782168
28 Vacuum Device for Hemostasis in Obstetrics and Gynecology: Proof of Concept Study in the Post Partum Hemorrhage Terminated NCT01589744
29 The Use of Fetal Fibronectin (fFN) in Predicting Preterm Delivery Due to Abruptio Placenta in Patients With Minor Maternal Trauma. Terminated NCT01279369
30 The Impact of Progesterone Treatment on Obstetrical Outcome Among Women With First Trimester Vaginal Bleeding Withdrawn NCT01501890 dihydroxyprogesterone caproate;Placebo

Search NIH Clinical Center for Placental Abruption

Cochrane evidence based reviews: abortion, threatened

Genetic Tests for Placental Abruption

Anatomical Context for Placental Abruption

MalaCards organs/tissues related to Placental Abruption:

40
Placenta, Uterus, Endothelial, Ovary, Cervix, Fetal Lung, Heart

Publications for Placental Abruption

Articles related to Placental Abruption:

(show top 50) (show all 3291)
# Title Authors PMID Year
1
Single inherited thrombophilias and adverse pregnancy outcomes. 54 61
17688607 2007
2
MTHFD1 R653Q polymorphism is a maternal genetic risk factor for severe abruptio placentae. 54 61
15633187 2005
3
Factor V Leiden and prothrombin G20210A mutations in pregnancies with adverse outcome. 61 54
12572596 2002
4
Combined heterozygosity for methylenetetrahydrofolate reductase (MTHFR) mutations C677T and A1298C is associated with abruptio placentae but not with intrauterine growth restriction. 54 61
11451544 2001
5
Genetic hypofibrinolysis in complicated pregnancies. 54 61
11152905 2001
6
[Protein C, protein S and antithrombin III at normal delivery and during abruptio placentae]. 54 61
10797988 1999
7
Resistance to activated protein C and the leiden mutation: high prevalence in patients with abruptio placentae. 54 61
9855597 1998
8
[Anticoagulant therapy in obstetrical disorders]. 61 54
2170703 1990
9
The comparison of placental abruption coupled with and without preeclampsia and/or intrauterine growth restriction in singleton pregnancies. 61
31248311 2021
10
Previous preterm cesarean delivery and risk of uterine rupture in subsequent trial of labor-a national cohort study. 61
33002499 2021
11
Evaluation of cord blood creatine kinase (CK), cardiac troponin T (cTnT), N-terminal-pro-B-type natriuretic peptide (NT-proBNP), and s100B levels in nonreassuring foetal heart rate. 61
31195859 2021
12
Parametric Regression-Based Causal Mediation Analysis of Binary Outcomes and Binary Mediators: Moving Beyond the Rareness or Commonness of the Outcome. 61
33693467 2021
13
Risk factors and outcomes of abnormal bleeding after external cephalic version. 61
33730770 2021
14
Attenuation imaging as a new ultrasonographic application for identifying placental haematoma. 61
33653845 2021
15
[Association of different stages of histological chorioamnionitis with respiratory distress syndrome in preterm infants with a gestational age of < 32 weeks]. 61
33691917 2021
16
Preeclampsia before 26 weeks of gestation: Obstetrical prognosis for the subsequent pregnancy. 61
33221560 2021
17
Endometriosis and assisted reproductive techniques independently related to mother-child morbidities: a French longitudinal national study. 61
33388264 2021
18
Factors associated with poor fetal outcome in placental abruption. 61
33264704 2021
19
Adverse Pregnancy Outcomes and Cardiovascular Disease Risk: Unique Opportunities for Cardiovascular Disease Prevention in Women: A Scientific Statement From the American Heart Association. 61
33779213 2021
20
Associations of thrombocytopenia, transaminase elevations, and transfusion with laboratory coagulation tests in women with preeclampsia: a cross-sectional study. 61
33798794 2021
21
Validation of the fullPIERS model for prediction of adverse outcomes in preeclampsia at a referral center. 61
33310390 2021
22
Inherited thrombophilia is significantly associated with severe preeclampsia. 61
33603868 2021
23
The value of the portable fibrinogen measuring device-a case report of severe postpartum hemorrhage with obstetric disseminated intravascular coagulation. 61
33687590 2021
24
Delivery characteristics in pregnancies with stillbirth: a retrospective case-control study from a tertiary teaching hospital. 61
33629576 2021
25
Intrapartum fetal monitoring and perinatal risk factors of neonatal hypoxic-ischemic encephalopathy. 61
32870345 2021
26
Perinatal and obstetric outcomes in singleton pregnancies following fresh versus cryopreserved blastocyst transfer: a meta-analysis. 61
33234401 2021
27
The etiology of stillbirth over 30 years: A cross-sectional study in a tertiary referral unit. 61
32959373 2021
28
Medically Indicated Late-Preterm and Early-Term Deliveries: ACOG Committee Opinion Summary, Number 818. 61
33481524 2021
29
Medically Indicated Late-Preterm and Early-Term Deliveries: ACOG Committee Opinion, Number 818. 61
33481529 2021
30
Easily generated hematological biomarkers and prediction of placental abruption. 61
33545414 2021
31
Placental abruption in each phenotype of hypertensive disorders of pregnancy: a retrospective cohort study using a national inpatient database in Japan. 61
33028989 2021
32
Cause of preterm birth and late-onset sepsis in very preterm infants: the EPIPAGE-2 cohort study. 61
33627822 2021
33
A case report of modified Porro caesarean hysterectomy on mother with hemorrhagic shock and severe anemia due to placental abruption. 61
33460885 2021
34
Prediction of Preeclampsia-Related Adverse Outcomes With the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor)-Ratio in the Clinical Routine: A Real-World Study. 61
33280406 2021
35
Cardiac and obstetric outcomes in pregnant patients with heart disease: a retrospective cohort study. 61
33632045 2021
36
Endometriosis and Risk of Adverse Pregnancy Outcome: A Systematic Review and Meta-Analysis. 61
33572322 2021
37
Maternal age at first cesarean delivery related to adverse pregnancy outcomes in a second cesarean delivery: a multicenter, historical, cross-sectional cohort study. 61
33579220 2021
38
New approach to the risk variables for administration of fibrinogen in patients with postpartum hemorrhage by using cluster analysis. 61
32967036 2021
39
Fetal Cardiac Interventions-Are They Safe for the Mothers? 61
33669554 2021
40
Altered erythropoiesis in newborns with congenital heart disease. 61
33531673 2021
41
[Efficacy analysis of different pulmonary surfactants in premature infants with respiratory distress syndrome]. 61
33729136 2021
42
Risk Factors for Atonic Postpartum Hemorrhage: A Systematic Review and Meta-analysis. 61
33417319 2021
43
[A multicenter study of the birth condition of preterm infants and the causes of preterm birth in Henan Province, China]. 61
33627204 2021
44
Pregnancy outcomes in nulliparous women with positive first-trimester preterm preeclampsia screening test: the Great Obstetrical Syndromes cohort study. 61
32777265 2021
45
CD15 immunostaining improves placental diagnosis of fetal hypoxia. 61
33545630 2021
46
Placental abruption in each hypertensive disorders of pregnancy phenotype: a retrospective cohort study using a national inpatient database in Japan. 61
32901155 2021
47
Pregnancy Outcomes of Women Hospitalized for Physical Assault, Sexual Assault, and Intimate Partner Violence. 61
33535860 2021
48
Exposure to chemical components of fine particulate matter and ozone, and placenta-mediated pregnancy complications in Tokyo: a register-based study. 61
33603097 2021
49
Elevated serum progesterone during in vitro fertilization treatment and the risk of ischemic placental disease. 61
33618055 2021
50
Placental Histopathology and Pregnancy Outcomes in "Early" vs. "Late" Placental Abruption. 61
32809128 2021

Variations for Placental Abruption

Expression for Placental Abruption

Search GEO for disease gene expression data for Placental Abruption.

Pathways for Placental Abruption

Pathways related to Placental Abruption according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.87 THBD SERPINC1 F5 F2
2 11.78 THBD SERPINC1 F5 F2
3
Show member pathways
11.71 MTRR MTHFR MTHFD1 BHMT
4 11.61 THBD NOS3 AGT
5
Show member pathways
11.54 PGF NOS3 FLT1
6
Show member pathways
11.43 PTGS2 PTGS1 MTRR MTHFR MTHFD1 F2
7 11.21 PTGS2 NOS3 FLT1 ENG
8 10.78 PTGS2 PTGS1 NOS3
9
Show member pathways
10.68 PGF FLT1
10 10.63 PTGS2 PTGS1

GO Terms for Placental Abruption

Cellular components related to Placental Abruption according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 SERPINC1 SERPINA7 PGF PAPPA HLA-G FLT1
2 endoplasmic reticulum lumen GO:0005788 9.46 SERPINC1 PTGS2 F5 F2
3 extracellular space GO:0005615 9.4 THBD SERPINC1 SERPINA7 PGF PAPPA HLA-G

Biological processes related to Placental Abruption according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 10.01 PTGS2 PGF FLT1 F2 AGT
2 oxidation-reduction process GO:0055114 9.99 PTGS2 PTGS1 NOS3 MTRR MTHFR MTHFD1
3 angiogenesis GO:0001525 9.89 PTGS2 PGF FLT1 ENG
4 cellular protein metabolic process GO:0044267 9.86 SERPINC1 PAPPA F5 F2
5 regulation of cell proliferation GO:0042127 9.85 PTGS2 PTGS1 ENG AGT
6 blood coagulation GO:0007596 9.83 THBD SERPINC1 F5 F2
7 female pregnancy GO:0007565 9.78 THBD PAPPA AGT
8 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.77 FLT1 F2 AGT
9 positive regulation of angiogenesis GO:0045766 9.76 PGF NOS3 FLT1 ENG
10 cellular response to mechanical stimulus GO:0071260 9.75 PTGS2 ENG AGT
11 regulation of blood pressure GO:0008217 9.71 PTGS2 PTGS1 NOS3 AGT
12 positive regulation of blood coagulation GO:0030194 9.62 F2 APOH
13 negative regulation of blood coagulation GO:0030195 9.62 THBD APOH
14 hemostasis GO:0007599 9.62 THBD SERPINC1 F5 F2
15 folic acid metabolic process GO:0046655 9.61 MTRR MTHFR MTHFD1
16 cyclooxygenase pathway GO:0019371 9.58 PTGS2 PTGS1
17 tetrahydrofolate interconversion GO:0035999 9.57 MTHFR MTHFD1
18 homocysteine metabolic process GO:0050667 9.54 MTRR MTHFR
19 regulation of blood coagulation GO:0030193 9.54 SERPINC1 F2 APOH
20 S-adenosylmethionine metabolic process GO:0046500 9.49 MTHFR BHMT
21 sulfur amino acid metabolic process GO:0000096 9.48 MTRR BHMT
22 negative regulation of fibrinolysis GO:0051918 9.43 THBD F2 APOH
23 negative regulation of platelet activation GO:0010544 9.33 THBD NOS3 F2
24 methionine metabolic process GO:0006555 9.13 MTRR MTHFR MTHFD1
25 methionine biosynthetic process GO:0009086 8.92 MTRR MTHFR MTHFD1 BHMT

Molecular functions related to Placental Abruption according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.63 PTGS2 PTGS1 NOS3 MTRR MTHFR MTHFD1
2 serine-type endopeptidase inhibitor activity GO:0004867 9.58 SERPINC1 SERPINA7 AGT
3 heparin binding GO:0008201 9.56 SERPINC1 PGF F2 APOH
4 flavin adenine dinucleotide binding GO:0050660 9.54 NOS3 MTRR MTHFR
5 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen GO:0016709 9.46 NOS3 MTRR
6 FMN binding GO:0010181 9.43 NOS3 MTRR
7 NADPH-hemoprotein reductase activity GO:0003958 9.32 NOS3 MTRR
8 NADP binding GO:0050661 9.13 NOS3 MTRR MTHFR
9 prostaglandin-endoperoxide synthase activity GO:0004666 8.62 PTGS2 PTGS1

Sources for Placental Abruption

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....